ZNTL : Insider Transactions for Zentalis Pharmaceuticals, Llc | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

Zentalis Pharmaceuticals, Llc (ZNTL)

$0.00 0.00 (0.00%) as of 4:30 Tue 11/30

Download

Exchange:

N/A

Security Type:

N/A

Shares Out:

84,924,000

Market Cap:

N/A

Last Volume:

0

Avg Vol:

0

52 Week Range:

$ - $

Level I Sector:

N/A

Level II Sector:

N/A

Level III Sector:

N/A

Member Indexes:

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : -

Guru Rank Value : -

Guru Occurances : -

Company Profile Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Co. is developing a pipeline of product candidates with an initial focus on validated oncology targets. Co. has two primary product candidates: ZN-c3, an inhibitor of Wee1, a protein tyrosine kinase, and ZN-c5, an oral selective estrogen receptor degrader. Co.'s other clinical product candidates include ZN-d5, a selective inhibitor of B-cell lymphoma 2 and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	22,000	22,000
Total Buy Value	$0	$0	$219,391	$219,391
Total People Bought	0	0	2	2
Total Buy Transactions	0	0	2	2
Total Shares Sold	3,356	32,218	167,164	362,029
Total Sell Value	$42,353	$375,045	$4,063,616	$8,774,551
Total People Sold	1	5	8	8
Total Sell Transactions	1	7	13	35
End Date	2024-02-15	2023-11-14	2023-05-16	2022-05-16

Adjust Filter Settings

Records found: 237

Page 4 of 10

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

Director

– • –

2022-03-07

4

AS

$44.90

$449,387

D/D

(10,000)

375,813

-

President & CEO

• • –

2022-03-02

4

AS

$50.11

$525,265

D/D

(10,471)

1,196,531

-

President & CEO

• • –

2022-03-01

4

AS

$49.74

$521,384

D/D

(10,471)

1,207,002

-

Epperly Melissa B,

Chief Financial Officer

• – –

2022-02-23

4

AS

$48.81

$93,921

D/D

(1,913)

264,494

-

Bunker Kevin D.

Chief Operating Officer

• – –

2022-02-22

4

AS

$47.08

$490,933

I/I

(10,000)

160,000

-

Director

– • –

2022-02-15

4

AS

$51.22

$519,295

D/D

(10,000)

385,813

-

Voliotis Dimitris

SVP, Clinical Development

• – –

2022-02-14

4

AS

$50.16

$30,188

D/D

(601)

15,978

-

Bunker Kevin D.

Chief Operating Officer

• – –

2022-02-14

4

AS

$50.16

$235,638

D/D

(4,688)

764,110

-

Chief Legal Officer

• – –

2022-02-14

4

AS

$50.16

$34,708

D/D

(691)

22,240

-

President & CEO

• • –

2022-02-14

4

AS

$50.16

$237,733

D/D

(4,733)

1,217,473

-

Director

– • –

2022-02-14

4

AS

$50.16

$360,775

D/D

(7,188)

395,813

-

Voliotis Dimitris

SVP, Clinical Development

• – –

2022-02-10

4

A

$0.00

$0

D/D

10,329

16,579

-

Bunker Kevin D.

Chief Operating Officer

• – –

2022-02-10

4

AS

$52.15

$534,995

I/I

(10,000)

170,000

-

Bunker Kevin D.

Chief Operating Officer

• – –

2022-02-10

4

A

$0.00

$0

D/D

22,481

768,798

-

Chief Legal Officer

• – –

2022-02-10

4

A

$0.00

$0

D/D

16,405

22,931

-

President & CEO

• • –

2022-02-10

4

A

$0.00

$0

D/D

50,431

1,222,206

-

Director

– • –

2022-02-10

4

A

$0.00

$0

D/D

15,798

403,001

-

Epperly Melissa B,

Chief Financial Officer

• – –

2022-02-10

4

A

$0.00

$0

D/D

16,405

266,407

-

Director

– • –

2022-02-07

4

AS

$52.77

$534,474

D/D

(10,000)

387,203

-

President & CEO

• • –

2022-02-02

4

AS

$57.87

$606,966

D/D

(10,471)

1,171,775

-

President & CEO

• • –

2022-02-01

4

AS

$56.81

$602,926

D/D

(10,471)

1,182,246

-

Voliotis Dimitris

SVP, Clinical Development

• – –

2022-01-20

4

AS

$60.52

$606,323

D/D

(10,000)

6,250

-

Voliotis Dimitris

SVP, Clinical Development

• – –

2022-01-20

4

OE

$18.00

$180,000

D/D

10,000

16,250

-

Bunker Kevin D.

Chief Operating Officer

• – –

2022-01-20

4

AS

$59.17

$599,912

I/I

(10,000)

180,000

-

Voliotis Dimitris

SVP, Clinical Development

• – –

2022-01-19

4

AS

$60.55

$607,931

D/D

(10,000)

6,250

-

237 Records found	1 2 3 4 5 6 7 8 9 Next	Page 4 of 10

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.